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1. Introduction 
Kidney cancer1 represents 2-3% of all diagnosed malignancies worldwide although in some 
Northern and Central European countries the incidence is higher, even 4-5% (Ferlay, 2010). 
Kidney cancer is responsible for approximately 116,000 deaths per year worldwide (Ferlay, 
2010). In the European Union (EU), the annual number of new kidney cancers was 73 171 in 
2008 (Ferlay, 2010). The majority of renal cell carcinomas (RCCs) arise from the cells of renal 
proximal tubules of nephrons, but 5% of cases from the cells of the collecting ducts (Chao et 
al. 2002, Kovacs et al. 1997, Störkel et al. 1997) (Figure 1.). Renal tumors are members of a 
complex family with unique histology, cytogenetic defects and variable metastatic potential 
(Linehan et al. 2003, Thoenes et al. 1986). Of all RCCs, 70-80% is of conventional type, also 
known as clear cell RCCs. Of these, approximately 75% have a mutation in the von Hippel-
Lindau tumor suppressor gene (VHL), in the short arm of chromosome 3 (Maxwell et al. 
1999, Gnarra et al. 1994).  
The annual increase in RCC incidence has been 2-4% since the 1970s (Finnish Cancer Registry 
2007, American Cancer Society 2004, Mathew et al. 2002). This has been attributed to the use of 
radiological imaging which is able to find presymptomatic RCC lesions (Jayson and Sanders 
1998), as well as the increased prevalence of etiologic risk factors, such as obesity (Chow et al. 
2000) and cigarette smoking (Hunt et al. 2005). The increase has been highest in localized 
disease, especially in tumors with less than 4 cm in diameter (Hollingsworth et al. 2006). 30-
60% of RCC tumors are found incidentally in abdominal imaging performed for some other 
reason than suspected renal tumor, such as the evaluation of non-specific musculoskeletal or 
abdominal complaints (Jayson and Sanders 1998). Macroscopic hematuria, palpable tumor and 
pain, together called the classic triad in RCC, indicate metastatic disease (Cunningham 1938). 
Metastatic disease is seen in 20-30% of RCC patients at diagnosis (Janzen et al. 2003, Mc 
                                                 
1 In epidemiological statistics, RCC and renal pelvis cancer are usually not reported separately, but 
combined under the heading of kidney cancer (Parkin et al. 2003). 
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Nichols et al. 1981). Half of the patients diagnosed with local RCC will later have a recurrence 
of their cancer: two thirds within the first year (Janzen et al. 2003), and the majority within five 
years (Lam et al. 2005, McNichols et al. 1981). The risk for late recurrence, at over 10 years from 
nephrectomy, is at least 10% (McNichols et al. 1981). 
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The number reflects the chromosome in which its genetic aberration is located. 
- means loss of function. 
+ means gain of function. 
p is the short arm of the chromosome. 
q is the long arm of the chromosome. 
Fig. 1. The genetic changes that characterize the different RCC subtypes according to the 
Heidelberg classification (Modified from Bodmer et al. 2002). 
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For those RCC patients with performance status enabling current treatments the expected 
five-year survival rate is slightly higher than 60% (Parkin et al. 2003). According to a few 
previous studies on long-term outcome for metastatic RCC (mRCC), the five-year survival is 
from 3% to 16% (Atzpodien et al. 2002, Motzer et al. 2000, Minasian et al. 1993) if 
metastasectomy has not been a possible treatment. For localized RCC, nephrectomy is the 
only curative treatment (Robson et al. 2002), and currently there is no adjuvant therapy in 
RCC. Possible treatments for mRCC, in addition to cytoreductive nephrectomy (Flanigan et 
al. 2001, Mickisch et al. 2001), are immunomodulators, such as interferon- (IFN-) (Kankuri 
et al. 2001, Pyrhönen et al. 1999), interleukin-2 (IL-2) (Négrier et al. 2007), and more recently 
tyrosine kinase inhibitors, such as sunitinib (Motzer et al. 2007), sorafenib (Escudier et al. 
2007), and mTOR inhibitor temsirolimus (Hudes et al. 2007). Everolimus, another mTOR 
inhibitor, has an encouraging antitumor activity against mRCC (Motzer et al. 2008). The 
efficacy of bevacizumab, an antiangiogenesis monoclonal antibody, has also been shown 
when used with IFN- (Bracarda et al. 2011, Rini et al. 2010, Yang et al. 2003). The Food and 
Drug Administration (FDA) and EU have also approved pazopanib, an angiogenesis 
inhibitor, with advanced RCC due to the efficacy of it in RCC (Sternberg et al. 2010). 
Ongoing clinical trials are addressing the role of targeted agents in adjuvant therapy in RCC 
(Choueiri et al. 2011). The efficacy of many potent novel targeted agents in RCC is under 
investigation in phase II and III trials, among these axitinib, a multitargeted tyrosine kinase 
receptor inhibitor (Goldstein et al. 2010), tivozanib, a pan-VEGFR tyrosine kinase inhibitor 
(De Luca and Normanno 2010), and ipilimumab, an anti-CTLA4 antibody (Yang et al. 2007). 
Additionally, vaccine therapy in RCC is being studied (Rini et al. 2011). The stabilization of 
the disease has been shown to be beneficial for the survival of mRCC patients (Thiam et al. 
2010, Kankuri et al. 2001). 
2. Staging and prognostic factors in RCC 
2.1 Pathological tumor staging 
In the 1960’s, Robson et al, created the staging system based on physical characteristics and 
tumor spread with the addition of tumor venous invasion (Robson et al. 2002). The poor 
correlation between the different Robson stages and survival led to the recommendation to 
use the TNM (tumor, node, metastases) staging system. Since 1978, the TNM classification 
system for the extent of the tumor spread has integrated characteristics such as tumor size, 
vascular involvement, nodal spread and distant metastases (Bassil et al. 1985, Harmen 1978). 
pTNM classification system was updated by the Union Internationale Contre le Cancer 
(UICC) and the American Joint Committee on Cancer (AJCC) in 1997 when the cut-off 
between T1 and T2 tumors was increased from 2.5 cm to 7 cm, in order to increase the 
difference in survival from these two tumor types. Analysis of outcome in nephrectomized 
patients showed that the 1997 TNM-system cut-off point between T1 and T2 tumors is too 
high, and a cut-off point of 4.5 – 5.0 cm has been suggested (Elmore et al. 2003, Zisman et al. 
2001). In 2002, the pTNM classification system was revised: T1 was divided into T1a and 
T1b by a cut-off point of 4 cm, according to the suitability for partial nephrectomy, and 
prognostication (Sobin and Wittekind 2002, Guinan et al. 1997). A uniform staging 
classification, the TNM staging system, has improved the division of patients into radical or 
partial nephrectomy candidates. Additionally, it has increased the co-operation between 
oncologists and pathologists concerning the outcome of RCC patients (Janzen et al. 2003, 
Javidan et al. 1999). Howerer, modifications in the TNM system may cause difficulty in 
comparing outcome data in different studies (Belldegrun et al. 1999, Störkel et al. 1989). 
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Pathological tumor stage (T-stage) has been observed to be the most important factor for 
locally confined RCC in predicting the survival of patients who have undergone 
nephrectomy (Kankuri et al. 2006, Delahunt et al. 2002). The observed five-year survival is 
approximately 75-80% for stage T1, 55% for T2, 40% for T3, and 20-30% for T4 (Sunela et al. 
2009, Tsui et al. 2000). For patients with stage I disease (tumor confined to the kidney) the 
five-year survival is approximately 90%, and for those with stage I and histologic of 
chromophobe type it is almost 100% (Zisman et al. 2001). The five-year survival rate for 
stage III disease is approximately 50% (Zisman et al. 2001). There is an 80% difference in 
survival rates between patients with local disease compared to those with advanced disease 
and distant metastases (American Cancer Society 2004). In a retrospective review of 2 473 
RCC patients from 1975 - 1985, regardless of T-stage, tumor size was observed to have an 
inverse association with survival (Guinan et al. 1995). In the study of Kankuri et al. (2006), in 
the analysis of those RCC patients who later developed metastatic disease, high T-stage 
caused twice the risk of metastatic disease and three times the risk of death compared with 
low T-stage which indicates that as the tumor size increases, the more aggressive its growth 
becomes and the more probable is tumor cell dissemination. T-stage is a prognostic factor 
for both metastases-free and overall survival in RCC patients. 
T-stage can be used in estimating the correct duration and frequency of surveillance of RCC 
patients after nephrectomy. RCC with a diameter of less than 3.0 cm grows slowly; only 
2.5% have metastases during the first three years (Bosniak et al. 1995). Therefore, in the 
treatment of those in whom surgery is contraindicated, careful monitoring (watchful 
waiting) by computed tomography (CT scan) may be used (Roberts et al. 2005, Bosniak et al. 
1995). Previously, it has been suggested that T-stage is not an important prognostic factor in 
the survival of patients who have neither lymph node nor distant metastases (Giuliani et al. 
1990). The therapeutic value of lymph node dissection remains unproven (Mickish 1999). T-
stage alone has been pointed to be a valuable prognostic factor for survival, even when the 
status of lymph nodes is unknown (Kankuri et al. 2006). Additionally, a high T-stage has 
been used as an inclusion criterion for adjuvant treatments in trials (Atzpodien et al. 2005, 
Repmann et al. 2003).  
Moreover, T-stage is an independent prognostic factor in mRCC patients (Kankuri-
Tammilehto et al. 2010). In the study of Kankuri-Tammilehto et al. (2010) high T-stage caused 
twice the risk of death compared with low T-stage in mRCC. The association between T-
stage and overall survival was also found in those with primary metastases at the time of 
nephrectomy (Kankuri et al. 2006). T-stage is not typically used in prognostic models in 
mRCC, a UCLA model (Zisman et al. 2002) being an exception. T-stage seems to be a good 
tool in prognostic evaluation in mRCC patients and could be included in prognostic models. 
2.2 Histopathological tumor grading 
In grading systems, the major criteria are nuclear and nucleolar appearances, while in some 
systems, tumor architecture and cell type is also included (Mostofi et al. 1998, Goldstein 
1997, Fuhrman et al. 1982, Syrjänen and Hjelt 1978, Skinner et al. 1971). The WHO grading 
system is based on the size and prominence of nucleoli (Eble et al. 2004, Mostofi et al. 1998), 
while the Fuhrman grading system is based on nuclear size, shape, and presence or absence 
of nucleoli (Fuhrman et al. 1982). The WHO grading system contains three grades, whereas 
the Fuhrman contains four. 
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Several studies have failed to demonstrate any statistically significant differences in the 
survival of patients with different grades, when all three or four grades are analyzed 
separately (Kankuri et al. 2006, Rioux-Leclercq et al. 2000, Usubutyn et al. 1998, Selli et al. 
1983) although when analyzing only the highest and the lowest grades the statistically 
significant difference in survival have been found (Kankuri et al. 2006). This is partly 
because, as yet, no consensus has been reached on a universal tumor grading system 
(Kanamaru et al. 2001, Medeiros et al. 1997). The observed five-year disease-specific survival 
(DSS) rate is approximately 90% for G1, 70-85% for G2, 45-60% for G3, and 15-30% for G4 
(Gudbjartsson et al. 2005, Ficarra et al. 2001). Currently, different grading systems are 
utilized at different institutions. Tumor-grading systems have been criticized because of 
their subjectivity in tumor evaluations (Lanigan et al. 1994), and comparison of different 
patient cases with respect to histopathological grade is difficult. More quantitative measures 
which describe the size or the shape of the nuclei have been requested by pathologists. In 
1997, an international consensus conference on RCC by UICC and AJCC outlined 
recommendations for the grading of RCC (Goldstein 1997): the grading system should be 
based on standardized and reproducible criteria that reflect the heterogeneity of nuclear and 
nucleolar features within a tumor, and each grade should result in significant differences in 
patient outcome. Recently again, a joint group of urologists and pathologists has published a 
proposal that the criteria for nuclear grading should be different for the different 
histopathologic subtypes of RCC according to the Heidelberg classification (Paner et al. 
2006). Additionally, reducing the grades in the Fuhrman system has been proposed, for 
better outcome stratification (Rioux-Leclercq et al. 2007, Lohse et al. 2002, Bretheau et al. 
1995). Overall, histopathological grade seem to be imprecise for prognostic evaluation in 
RCC patients (Uchida et al. 2002, Rioux-Leclercq et al. 2000, Lanigan et al. 1994). 
2.3 Heidelberg and WHO classifications for typing of renal tumors 
In Heidelberg, in October 1996, the morphology was combined with genetic findings for a 
new classification, called the Heidelberg classification of renal tumors, in a workshop 
organized by the UICC and the AJCC (Kovacs et al. 1997, Störkel et al. 1997). In addition to 
this, in 2004, WHO published the reassessed classification which is now based on both 
genetic and pathological abnormalities (Eble et al. 2004). Progress in our knowledge of 
genetic alterations leads to new suggestions for RCC entities (Eble 2003). With the progress 
of research, the Heidelberg classification may lead to more specific treatments in different 
subgroups of RCC patients. The 5-year DSS for locally confined RCC is for chromophobe 
RCC approximately 87-100%, for papillary RCC 87%, and for conventional RCC 70-75% 
(Cheville et al. 2003, Amin et al. 2002). In the case of sarcomatoid change, the survival 
decreases with the 5-year DSS of 35% (Amin et al. 2002). A very rare entity of collecting duct 
RCC is highly aggressive with highly decreased prognosis (Antonelli et al. 2003). The 
prognostic power of the Heidelberg classification has been investigated. The current 
Heidelberg classification does not have independent prognostic ability, and thus it should 
not be considered as a major prognostic variable comparable to T-stage and 
histopathological tumor grade (Patard et al. 2005). However, Heidelberg classification 
associates with metastases development, indicating that unclassified tumor type 
metastasizes with high probability (Kankuri et al. 2006). In future, with the progress of 
research, the Heidelberg classification may lead to more specific treatments in different 
subgroups of RCC patients (Störkel et al. 1997). 
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2.4 Prognostic models in RCC 
The heterogeneity of RCC within the same T-stage and grade (Tsui et al. 2000) has resulted 
in a need for prognostic models for prognostication and treatment modality selection. 
Prognostic models, anagrams and nomograms, have been developed to find those 
nephrectomized RCC patients who potentially have a long-term recurrence-free interval and 
survival, as well as those mRCC patients who have long-term survival (Table 1.). The most 
often represented as an independent prognostic factors in metastatic RCC (mRCC) are 
performance status, time to metastases, number of metastatic sites, and prior nephrectomy. 
Therapies for mRCC cause a wide variety of adverse effects, which reduce the quality of life. 
Determining the prognostic factors for survival in mRCC patients is valuable in directing 
therapy for those patients who would benefit from it. Several models have been developed 
for predicting the likelihood of response to therapy and to predict survival. However, novel 
biomarkers are hoped to specify the diagnosis, staging, and prognosis and to guide targeted 
cancer therapies. Molecular tumor markers are expected to revolutionize the staging of RCC 
in the future (Srigley et al. 1997), as nowadays stratifying the patients into risk groups is 
largely done on the basis of clinopathological factors, e.g. clinical stage of the disease. Still, 
all the molecular mechanisms that affect the development, progression and clinical behavior 
of RCC are not known. Advances in the understanding of the pathogenesis, behavior, and 
molecular biology of RCC may help to better predict tumor prognosis, and thus improve 
survival of RCC carcinoma patients when a more tailored therapy can be given to each 
individual patient. Molecular biomarkers, such as p53, Ki-67 and COX-2, are candidates for 
defining prognostic subgroups (Delahunt et al. 2002), and for guiding targeted therapies 
(Masters 2007), as shown in the studies, where p53, Ki-67 and COX-2 had prognostic value 
in predicting survival. The following chapters describe in more detail about the value of 
them in the prognosis in RCC. 
3. Biomarkers related to molecular mechanism in RCC 
3.1 pVHL, von Hippel-Lindau protein, mudulator of hypoxic response 
pVHL, a tumor suppressor gene product, is expressed especially in the kidney’s proximal 
renal tubule (Corless et al. 1997, Iliopoulos et al. 1995). Approximately 61-75% of sporadic 
conventional RCCs contain mutations in VHL, in the short arm of chromosome 3 (3p25-26) 
(van Houwelingen et al. 2005, Maxwell et al. 1999, Gnarra et al. 1994,), of which 50% show 
loss of heterozygosity (LOH) (Kovacs et al. 1997, Gnarra et al. 1994) and 10-20% silencing of 
the wild-type allele by promoter hypermethylation (Herman et al. 1994). VHL is associated 
with carcinogenesis. The function of pVHL is ubiquitylation of hypoxia-inducible factor 
(HIF); therefore, it modulates the hypoxic response; VHL protein can bind to hypoxia 
inducible factor-1 alpha (HIF-1) and target this factor for destruction in the presence of 
oxygen. HIF in turn controls the expression of several proteins, including carbonic 
anhydrase 9 (CA9) and proteins involved in angiogenesis, i.e. vascular endothelial growth 
factor (VEGF) and EPO, via oxygen-dependent ubiquitination (van Houwelingen et al. 2005, 
George and Kaelin 2003). Normally, VHL down regulates vascular endothelial growth factor 
(VEGF) by different pathways. In VHL-defective cancer cells, increased concentrations of 
VEGF and EPO are observed. 
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Reference Year No. of 
Patients
Therapy 
Administered
Tumor 
Subtype
Prognostic Factors Prognostic 
Information 
Motzer et al. 
(MSKCC) 
 
2002 463 IFN-   All Performance status, time from 
diagnosis to start of therapy, 
LDH, hemoglobin, corrected 
calcium 
 Survival 
Zisman et al. 
(UCLA) 
2002 262 IL-2 or IFN- 
(197 pts), 
other (65 pts) 
All T-stage, nodal involvement, 
nuclear grade, no. of 
symptoms, immunotherapy 
Survival 
Négrier et al. 
(Group 
Francais 
d'Immunother
apie)   
2002 782 IFN-  IL-2 All Performance status, no. of 
metastatic sites, disease-free 
interval, signs of 
inflammation, hemoglobin 
Survival, 
rapid 
progression 
Atzpodien 
(Medizinische 
Hochschule 
Hannover) 
2003 425 IFN- + IL-2 
 5-FU  
13CRA 
All Neutrophil count , LDH, CRP, 
time from diagnosis to start of 
therapy, no. of metastatic 
sites, bone metastases 
Survival 
Motzer et al. 
(MSKCC) 
2004 251 New agents All, if 
cytokine 
refractor
y disease
Performance status, 
hemoglobin, corrected 
calcium 
Survival for 
those who 
enter clinical 
trials of new 
agents  
Choueiri et al. 
(Cleveland 
Clinic 
Foundation) 
2007 358 IFN-  IL-2 
chemotherap
y 
All Performance status, 
hemoglobin, no. of metastatic 
sites, involved kidney of 
primary tumor 
Long-term 
survival 
Cho et al 
(Yonsei 
University) 
2008 197 Immunothera
py 
All Performance status, N stage, 
no. of metastatic sites, 
sarcomatoid differentiation, 
liver metastasis  
Survival 
Motzer et al. 
(MSKCC) 
 
2008 375 Sunitinib Conventi
onal 
RCC 
Performance status, time from 
diagnosis to start of therapy, 
nephrectomy status, no. of 
metastatic sites, presence of 
liver or lung metastases, 
LDH, corrected calcium, 
hemoglobin, alkaline 
phosphatase, thrombosytosis 
Probability of 
12-month 
progression-
free survival 
LDH=lactate dehydrogenase 
MSKCC = Memorial Sloan Kettering Cancer Center 
UCLA = University of California 
Table 1. Prognostic algorithms and nomograms for survival in mRCC between 2000 and 
2008. 
3.2 CA9, hypoxia associated enzyme  
CA9, a member of the carbonic anhydrase family, is suggested to play a role in the 
regulation of cell proliferation in response to hypoxic conditions. Low CA9 expression 
associates with the absence of VHL mutation and aggressive tumor characteristics in 
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conventional RCC (Pantuck et al. 2007). CA9 may indicate those patients who benefit from 
IL-2, as low CA9 expression associates with lower survival compared to high CA9 
expression in mRCC patients who receive IL-2 (Atkins et al. 2005, Bui et al. 2003). It has also 
been suggested that CA9 may indicate those patients who benefit from CA9-targeted 
therapies. It is also being investigated whether CA9 may indicate those patients who are 
potential candidates for adjuvant therapy.  
3.3 p53, biomarker of cell cycle point  
p53, a tumor suppressor gene product, is a promoter of cell growth arrest and apoptosis 
(Choisy-Rossi and Yonish-Rouach 1998). Activated p53 elicits several cellular responses, 
including apoptosis and cell cycle arrest (Reich and Levine 1984), and responds to DNA 
damage at the restriction checkpoint of the G1 phase of the cell cycle (May and May 1999). 
In normal cells, p53 is usually undetectable (Finlay et al. 1988). Mutant p53 accumulates in 
cell nuclei and can be immunostained (Reich and Levine 1984), whereas wild-type p53, 
because of its short half-life, is usually undetectable by routine immunohistochemistry 
(Reich and Levine 1984). p53 accumulation and increased cell proliferative activity are 
parallel phenomena in RCC (Kankuri et al. 2006, Pinto et al. 2005). p53 may be upregulated 
in part by VHL, accounting for some of the tumor suppressive functions of VHL in RCC 
(Galban et al. 2003). p53 seems to associate weakly with tumor grade, as the association was 
seen only in univariate analysis. Nor was an association between p53 and grade observed in 
a previous microarray study (Zigeuner et al. 2004). In both studies, the nuclear grade was 
determined according to the WHO guidelines. 
Published results on the association of p53 with survival have been controversial, some 
studies suggesting positive p53 associating with poor survival (Shvarts et al. 2005 , Zigeuner 
et al. 2004, Uchida et al. 2002, Haitel et al. 2000), while others have observed no association 
(Itoi et al. 2004, Olumi et al. 2001, Rioux-Leclercq et al. 2000, Hofmockel et al. 1996). In the 
study of Phuoc et al. (2007), p53 was significantly associated with survival in univariate 
analysis, but the association was not independent. In a tissue array study on metastasized 
patients, overexpression of p53 was associated with impaired DSS in renal carcinoma (Kim 
et al. 2004). In some studies, the association of p53 and survival has been investigated in a 
group of RCC patients with both locally confined and primary metastatic RCC; thus, patient 
selection varies in different studies (Olumi et al. 2001). The study of Kankuri et al. (2006) 
indicates that p53 is not able to predict which patients will develop metastatic disease after 
nephrectomy, but interestingly, they predict poor survival in mRCC patients (Figure 2.). 
Therefore, p53 can help in determining metastatic patients with a poor prognosis and, e.g. 
those who might benefit from aggressive treatment, such as high-dose interleukin-2 
(Spanknebel et al. 2005) or temsirolimus (Hudes et al. 2007). 
3.4 Ki-67, proliferation marker  
Ki-67, a proliferation biomarker, is expressed throughout the active phases of the cell 
cycle, and serves as a good marker for proliferative activity in cell nuclei (Gerdes et al. 
1984). Ki-67 accumulates during the cell cycle from G1 to mitosis, and is at its lowest level 
after mitosis (du Manoir et al. 1991). The percentage of nuclei staining by 
immunohistochemistry reflects Ki-67 expression (Olumi et al. 2001). An association 
between Ki-67 and high T-stage and metastases development have been observed 
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(Kankuri et al. 2006, Dudderidge et al. 2005, Rioux-Leclercq et al. 2000), indicating that Ki-
67 is a marker for aggressive disease in RCC with an increased risk of early metastases 
development. Ki-67 has been reported to independently predict survival following 
nephrectomy in many studies (Dudderidge et al. 2005, Bui et al. 2004, Itoi et al. 2004, 
Rioux-Leclercq et al. 2000, Aaltomaa et al. 1997). Ki-67 has been observed to increase in 
sarcomatoid change (Kanamaru et al. 1999), indicating different protein expression 
profiles in different entities according to the Heidelberg classification. 
 
Fig. 2. Kaplan-Meier survival curve for p53 in mRCC (n=66) (Kankuri et al. 2006).  
Dudderidge et al. (2005) found Ki-67 to be an independent prognostic factor for disease-free 
survival in nephrectomized RCC, but opposite results have also been published (Donskov et 
al. 2004, Kim et al. 2004, Yildiz et al. 2004). No association between Ki-67 alone and survival 
in locally confined RCC patients was found in the study of Kankuri et al. (2006). The 
differences in the classification of metastases are seen: Kim and coworkers (2004) classified 
both distant and local lymph node metastases as metastatic disease, whereas in the study of 
Kankuri et al. (2006), only tumors with distant metastases were classified as metastatic. 
However, Ki-67 predicts poor survival in mRCC patients (Figure 3.). Therefore, in addition 
to p53, Ki-67 can help in determining metastatic patients with a poor prognosis and, e.g. 
those who might benefit from aggressive treatment.  
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Fig. 3. Kaplan-Meier survival curve for Ki-67 in mRCC (n=66) (Kankuri et al. 2006). 
3.5 COX-2, biomarker for inflammation and neoplasia  
Cyclo-oxygenase-2 (COX-2), an isoform of the COX3 enzyme, is an inducible form of an 
enzyme involved in the first steps of prostaglandins and thromboxane synthesis. COX-2 
converts arachidonic acid first into prostaglandin G2, and afterwards by peroxidase activity 
into prostaglandin H2, a precursor of the prostaglandins (Taketo 1998). COX-2 is suggested 
to play a physiological role in fetal nephrogenesis (Khan et al. 2001). COX-2 increases in 
inflammation and neoplasia (Miyata et al. 2003, Hara et al. 2002, Nose et al. 2002, et al. Taketo 
1998), and is undetectable in most normal tissues (Mungan et al. 2006, Yoshimura et al. 2004). 
The conversion of procarcinogens to proximate carcinogens is catalyzed by the peroxidase 
activity of COX-2 (Elinq et al. 1990). COX-2 is highly induced by stimulus of oncogenes, 
cytokines, growth factors, and tumor promoters (Smith et al. 2000, Herschman 1996, 
Subbaramaiah et al. 1996). Associations between COX-2 over-expression and antiapoptotic 
ability, tumor invasiveness, tumor growth, angiogenesis, and immunosuppression, as well 
as multidrug resistance in cancer have been reported (Cao and Prescott 2002, Masferrer et al. 
2000, Subbramaiah et al. 1996, Tsujii and DuBois 1995). 
Cytoplasmic/membranous COX-2 staining by immunohistochemistry reflects COX-2 protein 
expression (Cho et al. 2005). The study results on associations of COX-2 with tumor stage, 
grade, and survival have been contradictory. Yoshimura et al. (2004) demonstrated that COX-2 
was expressed at its highest in G1, as well as in pT1 RCC tumors, compared to other RCC 
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tumors in grade and T-stage, while in Hashimoto et al’s study (2004), more COX-2 was found 
at the higher tumor grade, as well as stage. Kankuri-Tammilehto et al. (2010) found no 
association between COX-2 and tumor grade or T-stage.  A significant association has been 
observed between COX-2 and Ki-67 expression in the study of Miyata et al. (2003), whereas 
Kankuri-Tammilehto et al. (2010) found no association between them. No association between 
COX-2 and p53 has been found in studies (Kankuri-Tammilehto et al. 2010, Cho et al. 2005).  
Kankuri-Tammilehto et al. (2010) found that the proportion of COX-2 positive tumors is 
highest in RCC with the ability to develop later metastases, when compared to both RCC 
without metastatic potential and RCC with primary metastases. This finding was new. 
Previously, Miyata et al. (2003) observed that positive COX-2 expression associated with 
primary metastases in univariate analysis (when M0-patients were compared to M1-
patients). Cho et al. (2005) found no association between positive COX-2 expression and 
metastases (when M0-patients were compared to M1-patients, or appearance of metastatic 
disease was compared to non-metastatic disease). In those studies, the method of analysis 
differs from that of the study of Kankuri-Tammilehto et al. (2010), where patients were 
divided into three categories according to the appearance of metastases. According to the 
study of Kankuri-Tammilehto et al. (2010), metastases-free survival is longer in patients with 
COX-2 positive tumors. The median metastases-free survival was 46 months in RCC with 
COX-2 positivity compared to 15 months in RCC with COX-2 negativity (Figure 4.). These  
 
Fig. 4. The prognostic value of COX-2 for metastases-free survival from nephrectomy in 
RCC patients who later developed metastatic disease (n=32, Kaplan-Meier method): the 
median metastases-free survival time was 46 months with COX-2 positivity, and 15 months 
with COX-2 negativity  (Kankuri-Tammilehto et al. 2010). 
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results indicate that COX-2 positivity associates with the delay of metastatic formation in 
RCC patients who do not have disseminated disease at presentation, and that COX-2 
negativity associates with an aggressive phenotype in mRCC disease. 
Few studies have reported the results of an association between COX-2 expression and 
survival in RCC patients. Previously, Miyata et al. (2003) found that the five-year survival of 
patients with COX-2 positive tumors from nephrectomy was 66%, and of COX-2 negative 
patients 91% (Miyata et al. 2003). In Miyata’s study, the patients were 86% M0 and 14% M1 
at nephrectomy. Previously, no results of COX-2 and overall survival in mRCC patients 
have been published. The study of Kankuri-Tammilehto et al. (2010) indicates that COX-2 
positivity predicts improved overall survival in patients with mRCC treated with IFN-. 
This is in line with the previous study of Rini et al. (2006), in which COX-2 positivity 
associated with longer time to progression in the patients treated with celecoxib plus 
interferon-. Kankuri-Tammilehto et al. (2010) observed no association between COX-2 
staining and response to IFN- alone, while Rini et al. (2006) reported that all the RCC 
patients with objective responses to celecoxib plus interferon- expressed COX-2 staining. 
Additionally, COX-2 does not associate with the Heidelberg classification (Kankuri-
Tammilehto et al. 2010, Yoshimura et al. 2004). 
3.6 Her-2, biomarker of proto-oncogene product  
Her-2, a proto-oncogene product, is a member of the ErbB family of receptor tyrosine 
kinases. Her-2 functions in secretory epithelial tissues, and regulates intracellular signaling 
cascades (Arteaga et al. 2001, Olayioye et al. 2000). Her-2 is over-expressed in approximately 
20-30% of human adenocarcinomas (Latif et al. 2002, Lipponen et al. 1994, Slamon et al. 1989), 
and the over-expression is associated with metastatic phenotype and poorer prognosis, e.g. 
in breast and ovarian cancer (Slamon et al. 1989).  
Gene amplification of Her-2 can be investigated by cytogenetic analyses, such as fluorescent 
in situ hybridization (FISH), chromogenic in situ hybridization (CISH), and polymerase 
chain reaction (PCR). In breast cancer, FISH and CISH positivity are accurate predictors of 
response to trastuzumab (anti-Her2 therapy) (Isola et al. 2004, Lebeau et al. 2001). Receptor-
mediated targeted tumor therapy with Herceptin® (RhuMAb HER-2), a recombinant 
humanized monoclonal anti-Her-2 antibody, has improved the survival of breast carcinoma 
patients both in adjuvant therapy and in therapy for metastatic disease (Smith et al. 2007, 
Montemurro et al. 2003).  
Membranous staining of HER-2 in immunohistochemistry reflects HER-2 protein expression 
(Zhang et al. 1997). Her-2 receptor-specific tumor toxin, in an animal model, effectively 
reduced pulmonary tumors of advanced RCC (Maurer-Gebhard et al. 1998). Parallel 
associations of Her-2 expression between tumor stage and grade in RCC patients have been 
observed in many studies (Zhang et al. 1997, Stumm et al. 1996), although in the study of 
Seliger et al. (2000) no such association was found. In the study of Hofmockel et al. (1997), 
higher tumor grades were seen when Her-2 expression was low, and higher T-stage 
associated with high Her-2. In the study of Phuoc et al. (2007), Her-2 protein expression did 
not correlate with Ki-67 protein expression.  
In most HER-2 gene amplification studies, Her-2 gene amplification was observed neither by 
FISH analysis (Latif et al. 2002), messenger ribonucleic acid (mRNA) analysis (Stumm et al. 
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1996), nor PCR analysis (Selli et al. 1997, Zhang et al. 1997). Selli et al. (1997) found HER-2 
gene amplification in collecting duct RCC cases (45%). Therefore, HER-2 gene amplification 
may be more pronounced in collecting duct RCC, than in other more common RCC types 
(Matei et al. 2005, Zhang et al. 1997). The association of HER-2 gene amplification and HER-2 
protein expression with the prognosis of RCC patients has been estimated in few studies 
and the results have been contradictory (Phuoc et al. 2007, Lipponen et al. 1994). Further 
studies are needed to determine whether HER-2 protein expression or HER-2 gene 
amplification may be used as prognostic factors in RCC patients. 
3.7 Incidence of p53, Ki-67, and COX-2 expressions  
The incidence of p53- and Ki-67-positive expression in RCC tumors was low in RCC studies 
(Kankuri-Tammilehto et al. 2010, Kirkali et al. 2001, Haitel et al. 2000, Rioux-Leclercq et al. 
2000). It is known that in addition to melanoma, RCC belongs to tumors with a low 
incidence of p53 mutations compared to, e.g. prostate and bladder cancer (Haitel et al. 2000, 
Kirkali et al. 2001, Rioux-Leclercq et al. 2000). The low p53 mutation in different cancers 
(Olivier et al. 2002) and the low immunohistochemical staining of RCC tissue blocks for the 
p53 protein in studies (Haitel et al. 2000, Rioux-Leclercq et al. 2000) suggest that mutations in 
p53 result in an accumulation of the p53 protein. In the study of Oda et al. (1995), p53 
expression was found only in those components with p53 mutations, mainly in the 
sarcomatoid components. The 10% cut-off value of p53 and Ki-67 was often selected to 
achieve statistically reliable results, and in accordance with previous studies on the subject 
(Kankuri et al. 2006, Olumi et al. 2001). Previously published reports indicate that the 
proportion of COX-2 positive cells varies in human RCCs (Cho et al. 2005, Miyata et al. 2003). 
In the study of Kankuri-Tammilehto et al. (2010), weak intensity of COX-2 staining was 
considered as COX-2 negative, which resulted in a lower number of positive COX-2 cells 
than in some other RCC studies (Tuna et al. 2004, Cho et al. 2005). For comparison, in the 
study of Miyata et al. (2003), the criterion for positive COX-2 expression was 5%, whereas in 
the study of Kankuri-Tammilehto et al. (2010), it was considered to be 10%. Also different 
antibodies have been used in other studies (Rini et al. 2006, Cho et al. 2005, Hashimoto et al. 
2004). This fact and the criteria for immunohistochemical classification may contribute to the 
difference in the results. Validation of immunohistochemical methods is needed before the 
methods could be widely adopted for in clinical use. 
3.8 Combining markers 
In multivariate analysis, COX-2 and Ki-67 were independent variables, indicating that they 
are both stronger biomarkers than p53 for the development of metastases in RCC. However, 
combining markers may specify prognostic subgroups better than observing a single 
marker. As shown in a study by Haitel et al. (2000), p53 was not an independent predictor 
for survival, but p53 and mdm2, a negative regulator of p53, showed a strong association 
with poor survival. In the study of Kankuri et al. (2006), in RCC patients, double positivity 
for p53 and Ki-67 expression seems to indicate a higher probability of metastases than either 
marker alone. Additionally, combining COX-2 and Ki-67 increases their ability to predict 
survival in mRCC (Figure 5.). In this study, median overall survival time of RCC with COX-
2 negativity/Ki-67 positivity was 19 months, which was almost five times shorter than of 
RCC with COX-2 positivity/Ki-67 negativity. Median overall survival time of RCC with 
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COX-2 negativity alone was 28 months, which was three times shorter than that of RCC 
with COX-2 positivity.  
 
Fig. 5. The prognostic value of covariation of COX-2/Ki-67 for overall survival from 
nephrectomy in RCC patients with metastases (either primary presentation or later) (n=57, 
Kaplan-Meier method): the median overall survival time was 97 months with COX-2 
positivity/Ki-67 negativity, and 19 months with COX-2 negativity/Ki-67 positivity 
(p=0.004) (Kankuri-Tammilehto et al. 2010). 
Prognostic markers can be used in patient counseling, to select treatment modalities, and to 
determine eligibility for clinical trials. Different prognostic models have been created to 
specify the prognosis of RCC patients; they typically include conventional prognostic 
markers. However, combining biomarkers and conventional clinical markers seems to 
predict DSS more accurately than grade or TNM stage alone, both in locally confined and 
metastatic RCC (Kim et al. 2004).  
3.9 Trends in the use of biomarkers  
Prospective clinical trials on the clinical use of p53, Ki-67, and COX-2 protein expression in 
predicting overall survival could answer the question of whether the expression of these 
biomarkers can be reliably used in mRCC. These biomarkers cannot predict response to 
IFN- (Kankuri-Tammilehto et al. 2010). Whether these biomarkers can predict response to 
novel targeted therapies should be investigated in trials. The new era of genetic cancer 
studies shows great promise in terms of patient evaluation for new targeted therapies or 
immunotherapy. By means of the tissue microarray technique, thousands of tumors can be 
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investigated simultaneously to determine the protein expression profile. However, creating 
a consensus in the tissue microarray construction protocol is challenging, as RCC is a 
relatively large-size tumor of a highly heterogenous nature (Signoretti et al. 2008). At 
current, whole tissue sections are considered the gold standard, but the more cores per 
tumor are sampled the fewer errors are introduced by limited sampling. Using gene chips to 
profile kidney tumors defines the genes that determine patient survival and response to 
therapy, thus enabling precise prognosis determination and individual treatment planning 
(Tan et al. 2008). Additionally, tissue microarrays enable the analysis of protein expression 
profiles in specimens to determine their potential clinical significance and role in RCC 
biology. 
4. Conclusion 
RCC is an extremely heterogeneous disease, with patients having an overall survival from a 
few months to several years. For those RCC patients with performance status enabling 
current treatments, such as nephrectomy, immunomodulators, and more recently targeted 
therapies, the expected five-year survival rate has been slightly higher than 60%. Metastatic 
disease is seen in 20-30% of RCC patients at diagnosis. The five-year survival for metastatic 
RCC is from 3% to 16% if metastasectomy has not been a possible treatment. Currently, 
tumour (T)-stage is the best known prognostic factor for locally confined RCC. T-stage is a 
prognostic factor for both metastases-free and overall survival in locally confined RCC 
patients as well as in overall survival in metastatic RCC (mRCC). No consensus has been 
reached on a universal histopathologic tumor grading system. Several published reports 
have pointed out the differences in survival between the highest and the lowest tumor 
grades, even though when all three or four tumor grades were analyzed separatedly, the 
differences were no longer statistically significant. The heterogeneity of RCC within the 
same T-stage and grade has resulted in a need for more specific prognostic markers, related 
to molecular mechanisms of RCC, to specify diagnosis, staging and prognosis. Prognostic 
markers can also be used in to select treatment modalities, help in surveillance, and to 
determine eligibility for clinical trials. p53 associates weakly with tumor grade whereas Ki-
67 associates with T-stage and metastatic development, indicating that Ki-67 is a marker for 
aggressive disease in RCC with an increased risk of early metastases development. The 
proportion of COX-2 positive tumors is highest in RCC with the ability to develop later 
metastases, when compared to both RCC without metastatic potential, and RCC with 
primary metastases. Metastases-free survival is longer in patients with COX-2 positive 
tumors compared to COX-2 negative tumors. These data show that COX-2 negativity 
associates with an aggressive phenotype in mRCC disease. COX-2 and Ki-67 alone are 
stronger biomarkers than p53 for the development of metastases in RCC. Her-2 seems to 
associate with p53 and Ki-67, but results of associations between Her-2 and survival have 
been contradictory. Few studies have been published on the significance of Her-2 protein 
expression or Her-2 gene amplification in RCC, so more studies are warranted. p53 or Ki-67 
alone are not valuable prognostic markers in locally confined RCC, but they can predict 
poor survival in mRCC. Therefore, p53 and Ki-67 can help in determining metastatic 
patients with a poor prognosis and, e.g. those who would benefit from high-dose IL-2 or 
temsirolimus. COX-2 positivity predicts improved overall survival in patients with mRCC 
treated with IFN-. p53, Ki-67, and COX-2 cannot predict response to IFN-. Investigating 
the ability of p53, Ki-67, and COX-2 protein expression to predict overall survival in a 
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prospective clinical trial would answer the question of whether these biomarkers can be 
reliably used in mRCC. Combining the results of COX-2 and Ki-67 expression, may predict 
overall survival in mRCC. In predicting the development of metastases in nephrectomized 
RCC patients, COX-2 alone or a covariation of p53 and Ki-67 seem to have prognostic value. 
Combining p53 or COX-2 with Ki-67 may result in more specific prognosis staging in RCC 
than observing a single marker. In future, using the tissue microarray technique, the protein 
expression profile with several biomarkers can be determined quickly. Further 
investigations are needed on the reproducibility of staining of these novel biomarkers, and 
on validation of the ability of the expressions to discriminate clinical outcome in RCC. 
Findings on novel biomarkers have increased our understanding of the molecular biology of 
locally confined RCC patients and metastatic RCC patients. RCC is characterized by high 
resistance to radiation and chemotherapy, which may be due to the suppression of apoptotic 
mechanisms, such as the p53 tumour suppressor pathway. In RCC patients, Ki-67 
expression is not very high, which may partly explain RCC’s resistance to chemotherapy. 
Specification of the roles of novel tumor-related molecular prognostic factors might be 
translated into prognostic tools that could be used in clinical work.  
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